Top Markets
#1 OSK OSK +15.48%
#2 Ardor Ardor +7.80%
#3 MarsCoin MarsCoin +7.36%
#4 Tornado Cash Tornado Cash +6.57%
#5 HOME HOME +5.86%
#6 UnifAI Network UnifAI Network +4.33%
#7 AI XOVIA AI XOVIA +4.25%
#8 Story Story +4.12%
#9 Cash Cat Cash Cat +3.55%
#10 Anvil Anvil +2.93%
Coin of the day
OSK OSK
설정
언어
한국어
통화
USD
테마
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
주식 순위 #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
주가
$4.64
마지막 동기화: 2022-09-12
시가총액
$293.43M
변동 (1일)
0.87%
변동 (1년)
0.00%
국가
US
거래 Adagio Therapeutics, Inc. (ADGI)

카테고리

Healthcare
Adagio Therapeutics, Inc. (ADGI)의 매출
Sep 2026 기준 매출 TTM: 0
Adagio Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Adagio Therapeutics, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH